LINC-ROR and neoplasm: Our results provide a plausible link between LINC-ROR rs2027701 polymorphisms and efficacy at the lymph node 3 months after CRT (OR = 2.266, 95%CI = 1.020–5.033, P = 0.045), while no significant difference was found on the primary tumour.